DelveInsight's "Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Antibody-mediated Rejection market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Antibody-mediated Rejection market shares of the individual therapies, a detailed current Antibody-mediated Rejection treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Antibody-mediated rejection (AMR)—or humoral rejection after renal transplantation is a devastating event that inevitably led to allograft loss. AMR poses a significant and continued challenge for long term graft survival in kidney transplantation.
Antibody-mediated Rejection Market Key Facts
- As per the study conducted by Valenzuela et al. (2017), the incidence tends to be higher (up to 40%) in pediatric and medication-nonadherent adult transplant patients, with the latter constituting nearly two-thirds of adult transplant patients by 12 years after transplantation. Antibody-mediated Rejection incidence among pre-sensitized patients is more than 20%.
- According to the study conducted by Puttarajappa et al. (2012), acute AMR occurs in about 5–7% of all kidney transplants and is responsible for 20–48% of acute rejection episodes among pre-sensitized positive crossmatch patients.
- The study conducted by Nguyen et al. (2018), estimated that women are at higher risk of Antibody-mediated Rejection than men.
- As per the study conducted by Calp-Inal et al. (2016), the incidence of acute and chronic AMR was 45% and 36% in patients with C1q+DSA. The study indicated that the presence of C1q+ DSA was associated with acute and chronic AMR.
Antibody-mediated Rejection Market Share
The Antibody-mediated Rejection market analysis section of the report helps to understand the current and forecasted Antibody-mediated Rejection market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Antibody-mediated Rejection market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Antibody-mediated Rejection Epidemiology Forecast
The Antibody-mediated Rejection epidemiology section covers insights about historical and current Antibody-mediated Rejection patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Antibody-mediated Rejection Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Antibody-mediated Rejection Epidemiology Segmentation
- Incident Population of Antibody-Mediated Rejection
- Gender-specific Incident Population of Antibody-Mediated Rejection
- Type-specific Incident Population of Antibody-Mediated Rejection
- Treatable Cases of Antibody-Mediated Rejection
The primary aims of therapeutic approaches to Antibody-mediated rejection is to remove circulating donor-specific anti-HLA antibodies and to block their effects, reduce their production, or both. Major Key players worldwide are working to develop a therapy for AMR. Antibody-mediated Rejection Companies -
- CSL Behring
- Bristol-Myers Squibb
- Hansa Biopharma AB
And others.
Antibody-mediated Rejection Therapies covered in the report include Imlifidase, Daratumumab, Clazakizumab, C1‐INH, and many more.
For more details, visit: Antibody-mediated Rejection Market Share